Results:
Proven to reduce reinterventions by 50%
The Zilver PTX (paclitaxel) drug-eluting stent has been proven to reduce reintervention rates in the SFA (superficial femoral artery) by 50% when compared to other leading stents.1 Combine our next-generation durability with our 100% polymer-free paclitaxel drug delivery, and you have a tremendously powerful weapon against peripheral disease. Learn More »
1. Dake M. Interim analysis of two-year results for the Zilver PTX drug-eluting peripheral stent. Presented at: CIRSE 2009; September 21, 2009; Lisbon Portugal.Video:
Instructions for Use:
Please refer to the Zilver PTX IFU for indications, contraindications, warnings, precautions and potential adverse events. PDF Download »
Advancing Leg Therapies
